Please assess the completion status of the following clinical trial:

Trial Title: The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For inclusion in the study patients should fulfill the following key criteria:~1. Informed Consent can be obtained prior to any study procedures.~2. Patient is able to read, understand and sign the Informed Consent.~3. HbA1c ≥ 8.0% and ≤ 11.0% based on laboratory results~4. Currently treated with a stable TDID ≥ 80 U at least 3 months prior to enrolment~5. Patients who are receiving metformin must be on a stable total daily dose ≥ 1500 mg or the maximum tolerated dose of metformin within 3 months prior to enrolment~6. BMI of ≥ 30 kg/m2 at enrolment~7. Male or female and ≥18 and ≤75 years old at time of informed consent~8. For female patients:~   * Not breastfeeding.~  * Negative pregnancy test result (human chorionic gonadotropin, beta subunit \[βhCG\]) at Visit 0 (Screening) and Visit 1 (randomization) -not applicable to hysterectomized and post-menopausal females.~  * If of childbearing potential (including perimenopausal women who have had a menstrual period within 1 year), must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, ie, less than 1% per year, when used consistently and correctly, such as implants, injectables, hormonal contraceptives \[pills, vaginal rings, or patches\], some intrauterine contraceptive devices \[levonorgestrel-releasing or copper-T\], tubal ligation or occlusion, or a vasectomized partner) during the entire duration of the study. As applicable, all methods must be in effect prior to receiving the first dose of study medication.~  * Must practice appropriate birth control as stated above for 10 weeks after the last dose of study medication.~9. Patients who are receiving the following medications must be on a stable treatment regimen for a minimum of 2 months prior to Visit 0 (Screening):~   * Antihypertensive agents~  * Thyroid replacement therapy~  * Antidepressant agents~Exclusion Criteria:~1. Diagnosis of Type 1 Diabetes~2. History of diabetic ketoacidosis, hyperosmolar coma or corticosteroid-induced Type 2 diabetes~3. Patients with significant thyroid disease~4. Patients with history of acute or chronic pancreatitis~5. Clinically significant cardiovascular disease or procedure within 3 months prior to enrolment or expected to require coronary revascularization procedure~6. Presence of history of severe congestive heart failure (NYHA III and IV)~7. Creatinin-Clearance of \< 60 ml/min based on local laboratory results~8. Concomitant medication with loop diuretics~9. Patients who, as judged by the investigator, may be at risk for dehydration or volume depletion that may affect the patient's safety (including e.g. patients with a history of Diabetes insipidus)~10. Pregnant women~11. Administration of any other antidiabetic therapy, other than insulin (see inclusion criterion no.4 and 5) and metformin with a stable total daily dose ≥ 1500 mg or the maximum tolerated dose of metformin within 3 months prior to enrolment~12. History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥ 700 mg/dL (≥ 7.98 mmol/L) at Visit 0 (Screening).~13. History or presence of inflammatory bowel disease or other severe GI diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis.~14. History of gastric bypass surgery or gastric banding surgery, or either procedure is planned during the time period of the study. Current use of gastric balloons is also excluded.~15. Significant hepatic disease, including, but not limited to, acute hepatitis, chronic active hepatitis, or severe hepatic insufficiency, including patients with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>3x upper limit of normal (ULN) and/or total bilirubin (TB) \>2 mg/dL (\>34.2 μmol/L) (patients with TB \>2 mg/dL \[\>34.2 μmol/L\] and documented Gilbert's syndrome will be allowed to participate).~16. Known history of hepatotoxicity with any medication~17. Known history of severe hepatobiliary disease.~18. Positive serological test for hepatitis B or hepatitis C.~19. Known or suspected human immunodeficiency virus (HIV) infection.~20. History of organ transplantation.~21. Presence or history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2) OR a family history of medullary thyroid carcinoma or MEN 2.~22. Malignancy (with the exception of basal and squamous cell carcinoma of the skin) within 5 years of Visit 0 (Screening).~23. Hemoglobinopathy, hemolytic anemia, or chronic anemia (haemoglobin concentration \<11.5 g/dL \[115 g/L\] for males, \<10.5 g/dL \[105 g/L\] for females) or any other condition known to interfere with the HbA1c methodology.~24. Patients with abnormal test results of hematocrit (hematocrit \> 50% for men; hematocrit \> 47% for women)~25. Has donated blood or had a significant blood loss within 2 months of first dose of study medication or is planning to donate blood during the study.~26. Has donated plasma within 7 days prior to first dose of study medication.~27. Any exposure to Exenatide (including BYETTA®, BYDUREON, or exenatide suspension).~28. Any exposure to Dapagliflozin or any SGLT-2 inhibitor.~29. Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:~    * Any DPP-4 inhibitor within 3 months prior to Visit 0 (Screening).~   * Any GLP-1 analog within 1 year prior to Visit 0 (Screening).~   * Systemic corticosteroids within 3 months prior to Visit 0 (Screening) by oral, intravenous, intra-articular, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR) steroids known to have a high rate of systemic absorption. For examples of excluded steroids, refer to Section 7.7.~   * Prescription or over-the-counter weight loss medications within 3 months prior to Visit 0 (Screening).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin plus Exenatide (Type: EXPERIMENTAL): Dapagliflozin (10mg orally once daily) plus Exenatide (2mg subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
- Placebo plus Placebo (Type: PLACEBO_COMPARATOR): Placebo (film-coated tablet once daily) plus Placebo (subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
- Placebo plus Exenatide (Type: ACTIVE_COMPARATOR): Placebo (film-coated tablet once daily) plus Exenatide (2mg subcutaneous once- weekly injection) as add-on to high dose intensive insulin therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues